Loading
A phase 1/2 trial of tulmimetostat with PD-1 blockade in advanced non-small-cell lung cancer, run by VA Office of Research and Development, now recruiting.
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05467748 by VA Office of Research and Development, with VA Greater Los Angeles Healthcare System as collaborator; 66 participants are planned, it started on 2025-12-08; the registry gives 2027-12-08 as its primary completion date. Interventions recorded: Tulmimetostat. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Tulmimetostat and the tag pipeline.
Shares Tulmimetostat and the tag pipeline.
Shares Tulmimetostat and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/